StockData
Cadrenal Therapeutics, Inc. logo

Cadrenal Therapeutics, Inc. (CVKD) stock

CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/30
$1.88+0.48 (+34.29%)

Close on Nov 17, 2026Market cap $6.71MP/E –Yield 877.66%

Cadrenal Therapeutics cash

Cash and short-term investments held at the end of each period.

Cadrenal Therapeutics's cash was $2.39M at Jun 30, 2026. For fiscal 2025 it was $4.01M, down 60.0% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.01M-60.0%
FY2024Dec 31, 2024$10.02M+19.2%
FY2023Dec 31, 2023$8.40M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.39M-57.1%
Q1 FY2026Mar 31, 2026$2.31M-68.5%
Q4 FY2025Dec 31, 2025$4.01M-60.0%
Q3 FY2025Sep 30, 2025$3.86M-11.5%
Q2 FY2025Jun 30, 2025$5.57M+10.6%
Q1 FY2025Mar 31, 2025$7.34M+11.7%
Q4 FY2024Dec 31, 2024$10.02M+19.2%
Q3 FY2024Sep 30, 2024$4.36M-52.1%
Q2 FY2024Jun 30, 2024$5.04M+25.0%
Q1 FY2024Mar 31, 2024$6.57M–
Q4 FY2023Dec 31, 2023$8.40M–
Q3 FY2023Sep 30, 2023$9.11M–
Q1 FY2023Mar 31, 2023$4.03M–

More Cadrenal Therapeutics figures

See a number that looks wrong?